Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15436268 | 0.94 | JAK2 (0.49) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL15436276 | 0.88 | JAK2 (0.48) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL30007484 | 0.85 | JAK2 (0.53) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL1366925 | 0.84 | JAK2 (0.54) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL1367257 | 0.84 | JAK2 (0.54) | JAK2JAK3JAK1TYK2PRCP | |
| Hydrochloric Acid SCHEMBL1365552 | 0.83 | JAK2 (0.53) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL1368417 | 0.83 | JAK2 (0.52) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL1368415 | 0.83 | JAK2 (0.52) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL1365710 | 0.83 | JAK2 (0.52) | JAK2JAK3JAK1TYK2PRCP | |
| SCHEMBL1368012 | 0.82 | JAK2 (0.55) | JAK2JAK3JAK1TYK2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | claimed |
| US-20080045588-A1 | Preparation and utility of substituted amphetamines | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045588-A1 | Preparation and utility of substituted amphetamines | PNMT, TAAR5, COMT | JAK2 3459/4885JAK3 2936/4885JAK1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.